Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Clinical trial NCT06695130 · COMPLETED

Trial details

NCT number: NCT06695130
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

COVID-19 Immunization Influenza Immunization

Start date: 2024-11-18
Primary completion: 2026-04-03
Enrollment: 980

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.